MedPath

Minimally Displaced Femoral Neck Fracture Pilot Study

Not Applicable
Recruiting
Conditions
Femoral Neck Fractures
Interventions
Procedure: Arthroplasty
Procedure: Internal Fixation
Registration Number
NCT05947058
Lead Sponsor
University of Maryland, Baltimore
Brief Summary

The goal of this randomized pilot study is to assess feasibility of the trial and to collect information to inform the design of a definitive trial. Adult patients ages 60 years or older with a low-energy minimally displaced femoral neck fracture (FNF) treated with surgery will be eligible to participate in the study. Patients will be randomized to one of two treatment groups, hip arthroplasty or internal fixation. Participants will be followed for 1 year.

Detailed Description

Nearly half of all elderly hip fractures are femoral neck fractures (FNFs) and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this significant practice change remains lacking.

The eventual definitive trial has significant potential to change clinical practice and optimize patient outcomes for individuals that experience a minimally displaced FNF. Treating minimally displaced FNFs with arthroplasty, instead of internal fixation, would be a paradigm shift in clinical care. This pilot study will demonstrate feasibility of the definitive trial and be used to refine aspects of the study protocol as necessary. If feasibility is successfully demonstrated, the pilot activities will be considered a vanguard phase for the definitive clinical trial.

Adult patients ages 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery will be eligible to participate in the study. Patients will be randomized to receive either hip arthroplasty or internal fixation. Patients will be followed for 1 year, with visits occurring at 6 weeks, 4 months, 8 months, and 1 year after fracture. At each follow-up, mortality, ambulation, days at home, and health status will be collected.

The primary objective is to assess feasibility of the trial and to collect information to inform the design of the definitive trial. The feasibility outcomes will include participant enrollment, adherence to treatment allocation, data collection methods, and compliance with key aspects of the protocol.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Patients 60 years of age or older.
  • Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging (MRI).
  • Minimally displaced fracture that could be, in the judgment of the attending surgeon, optimally managed with either arthroplasty or in situ internal fixation without reduction.
  • Low energy injury mechanism defined as a fall from standing height.
  • Informed consent obtained from patient or proxy.
  • Surgeons with expertise in total hip arthroplasty, hemiarthroplasty, and internal fixation are available to perform surgery. Note: Surgeons do not need to be experts in all techniques.
Read More
Exclusion Criteria
  • Unable to ambulate 10 feet pre-injury with any assistance.
  • Associated lower extremity injury that prevents post-operative weightbearing.
  • Retained hardware around the hip that precludes either study treatment.
  • Infection around the hip (soft tissue or bone).
  • Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
  • Patient is too ill, in the judgement of the attending surgeon, for internal fixation.
  • Patient is too ill, in the judgement of the attending surgeon, for arthroplasty.
  • Unable to obtain informed consent due to language barriers.
  • Problems, in the judgment of study personnel, with maintaining follow-up with the patient.
  • Currently enrolled in a study that does not permit co-enrollment.
  • Prior enrollment in the trial.
  • Other reason to exclude the patient, as approved by the Methods Centre.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ArthroplastyArthroplastyA modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. We recommend surgeons consider a total hip arthroplasty for younger active, independent participants; conversely, a hemiarthroplasty is recommended for more frail, lower-demand participants. Similarly, cemented arthroplasty for older adult participants is also recommended. The surgical approach and the use of post-operative hip precautions will be determined by the treating surgeon.
Internal FixationInternal FixationBased on the fracture displacement eligibility criteria, minimal or no reduction is expected during the surgical procedure. However, the treating surgeon will be allowed to perform fracture reduction maneuvers if desired. Fixed angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. If using multiple cancellous screws, an inverted triangle or similar screw pattern is recommended. Fixed angle devices, such as a sliding hip screw (with or without an anti-rotation screw) or newer multi-screw fixed angle devices will also be permitted. Internal fixation constructs combining cancellous screws and fixed angle devices will be permitted.
Primary Outcome Measures
NameTimeMethod
Feasibility of Participant Enrollment12 months

Participant enrollment will be assessed by monitoring screening and enrollment metrics, including:

* Proportion of clinical sites initiated and able to screen consecutive patients with minimally displaced FNF

* Proportion of patients who are screened for eligibility to participate in the trial

* Proportion of patients who meet the eligibility criteria

* Proportion of patients who provide informed consent

* Proportion of time required to enroll at least four participants per clinical site

* Proportion of reasons for exclusion.

Feasibility of Treatment Allocation12 months

Feasibility of the treatment allocation will be assessed using the following metrics:

* Adherence to arthroplasty treatment allocation

* Adherence to internal fixation treatment allocation

Refine Data Collection Methods12 months

To refine the data collection methods, the following metrics will be reviewed:

* Proportion of participants with missing data

* Review of missing data to identify data fields that are not feasible to collect

* Data errors to identify ways to improve the flow of the case report forms (CRFs) and data collection

Assess Protocol Compliance12 months

The following metrics will be used to assess compliance with the protocol:

* Proportion of randomization errors

* Proportion of participants who complete each follow-up visit

* Proportion of participants who withdraw from the trial (withdrawal of consent)

* Proportion of participants who cannot be located (loss to follow-up)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (9)

Vall d'Hebron University Hospital

πŸ‡ͺπŸ‡Έ

Barcelona, Spain

University of Southern California

πŸ‡ΊπŸ‡Έ

Los Angeles, California, United States

Yale University

πŸ‡ΊπŸ‡Έ

New Haven, Connecticut, United States

University of Florida

πŸ‡ΊπŸ‡Έ

Gainesville, Florida, United States

University of Maryland, R Adams Cowley Shock Trauma Center

πŸ‡ΊπŸ‡Έ

Baltimore, Maryland, United States

University of Maryland Capital Region Health

πŸ‡ΊπŸ‡Έ

Largo, Maryland, United States

Dartmouth-Hitchcock Medical Center

πŸ‡ΊπŸ‡Έ

Lebanon, New Hampshire, United States

Inova Fairfax Medical Campus

πŸ‡ΊπŸ‡Έ

Falls Church, Virginia, United States

Hamilton Health Sciences

πŸ‡¨πŸ‡¦

Hamilton, Ontario, Canada

Β© Copyright 2025. All Rights Reserved by MedPath